StockNews.AI
DRCT
StockNews.AI
71 days

MUSE Microscopy, Inc. Launches Veterinary Digital Pathology with the First-of-Its-Kind Tissue-to-Direct Digital Imaging for the Veterinary Market

1. MUSE Microscopy launched a new veterinary digital pathology subsidiary. 2. Aim for same-day results in tissue biopsies boosts vet diagnostics. 3. Leadership includes experienced professionals from the veterinary industry. 4. Technology promises real-time imaging and faster clinical decisions. 5. Veterinary sector expected to embrace innovative diagnostic capabilities.

9m saved
Insight
Article

FAQ

Why Bullish?

MUSE's expansion into veterinary diagnostics could drive growth and innovation in pathology. Historically, successful entries into niche markets have benefited companies significantly.

How important is it?

The article discusses a significant market expansion by MUSE Microscopy, presenting long-term growth opportunities. Positive sentiment from strategic leadership and technology advancements indicates strong potential for stock impact.

Why Long Term?

The development of MUSE Veterinary Digital Pathology will take time to establish a market presence. However, the long-term potential for improvements in veterinary care and operational efficiency is substantial.

Related Companies

MUSEVCATRUPTHRI
IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MUSE Microscopy, Inc., a pioneer in digital pathology innovation, today announced the formation of MUSE Veterinary Digital Pathology, LLC, a wholly-owned subsidiary focused on transforming pathology through point-of-care service. This initiative aims to provide same-day results for tissue biopsies. This new service will provide the gold standard of patient care allowing veterinarians to deliver pet parents with diagnosis, prognosis, and treatment plans efficiently using the SmartPath MUSE Technology™ (SmartPath)* Platform. The strategic move signifies MUSE’s formal entry into the veterinary health market, bringing point-of-care and real-time diagnostic imaging to specialty, emergency, and family veterinary practices nationwide. Utilizing the unique capabilities of SmartPath for rapid, non-destructive tissue imaging, MUSE Veterinary Digital Pathology empowers veterinarians to make real-time treatment decisions, marking a significant innovation in tissue pathology in the past century. Matthew Nunez, CEO of MUSE Microscopy, will lead MUSE Veterinary Digital Pathology supported by a seasoned executive, Darin Nelson, who has a proven track record in building and scaling veterinary diagnostic companies. He acquired more than 800 animal hospitals for both VCA and Thrive Pet Healthcare and helped pet insurer Trupanion go public. Darin will join the company as President. Dr. Jeffrey Edwards, DVM, MPH, MRVCS, DAVCP, a clinical leader in veterinary diagnostics in his storied career, has been appointed as Chief Medical Officer overseeing the anatomic pathology team and the translational adoption of our innovative technology in veterinary practices nationwide.. “This launch represents a natural and strategic expansion of our technology platform,” stated Matthew Nunez. “The veterinary sector is primed for innovation in diagnostic speed and precision. With MUSE Veterinary Digital Pathology, we are delivering state-of-the-art digital pathology directly to the point-of-care, empowering veterinarians to deliver faster diagnoses, reduce unnecessary delays, and elevate patient care.” MUSE Veterinary Digital Pathology will initially target specialty and emergency practices and large general practices, expected to commence in Q4 2025. The platform's intraoperative capabilities, same day results, and SmartPath’s tissue-to-digital imaging will provide real-time surgical margin assessments and tissue diagnostics without reliance on current conventional slide-based workflows. “This is about putting powerful diagnostic tools directly into the hands of veterinarians when and where they need them most,” stated Darin Nelson. “Our goal is to enable faster decision-making, minimize wait times, and ultimately improve clinical outcomes for animal patients.” “Veterinary medicine is long overdue for this level of innovation,” added Dr. Jeffrey Edwards. “With our groundbreaking technology, we can reduce the delay in receiving biopsy results currently requiring couriers and 3-7 days down to same day diagnosis, changing the entire dynamic of medical management and clinical decision making as well as alleviated owner anxiety of waiting.” MUSE Veterinary Digital Pathology will operate independently while leveraging MUSE Microscopy’s existing infrastructure, regulatory framework, personnel, and proprietary imaging technologies. The company anticipates additional announcements in the coming months, including pilot partnerships and distribution opportunities across the U.S. and internationally. About MUSE Microscopy, Inc. MUSE Microscopy is a company that specializes in the application of Microscopy with Ultraviolet Surface Excitation (MUSE). We have developed a MUSE-enabled imaging system for diagnostic assistance in pathology, and research applications. Our commercial product, SmartPath MUSE Technology™ (SmartPath)*, is a slide-free direct-to-digital imaging platform that aims to transform the patient’s experience and provide healthcare professionals with quick diagnostic information through digital imaging. To learn more, you can visit their website at https://musemicroscopy.com/ or find them on social media platforms such as Twitter, Facebook, and LinkedIn. *Pending FDA approval. Limits on AccuracyThis press release is intended to provide information about MUSE Microscopy, Inc.’s research and potential product. Information is believed to be accurate at the time it is created. However, like any printed material, information may become outdated over time. Information may contain technical inaccuracies or typographical errors. Information may be changed or updated without notice. There may also be improvements or changes in the products and services described in this press release at any time without notice. It is important that you rely on the advice of an appropriate professional. Nothing contained in any presentation is to be construed as medical, legal, investment, financial, or other advice. This information is not intended to be a substitute for such advice. MUSE Microscopy, Inc., does not endorse any specific techniques or methods of treatment. Individuals are advised to consult their health care professionals for full information about the potential adverse reactions from use of the medical technologies discussed in this press release. We will use reasonable efforts to include accurate and up-to-date information on the website, but MUSE Microscopy, Inc. makes no warranties or representations as to its accuracy. Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans, prospects, and assumptions regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “termed,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.  Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.  MEDIA CONTACT:Matthew NuñezTel: 949.813.6121 mnunez@musemicroscopy.com Source: MUSE Microscopy, Inc.  Join the Evolution. Embrace the Future. #DigitalPathology #SlideFreeRevolution #SmartPathMUSE For more information about MUSE Microscopy and its innovative technologies, please visit www.musemicroscopy.com.

Related News